TriangleNALIRIFOX (NCT07163273)
NALIRIFOX trial for Pancreatic Ductal Adenocarcinoma (NCT07163273). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic pancreatic ductal adenocarcinoma, adenosquamous or poorly differentiated carcinoma, without prior chemotherapy for metastatic disease. Known BRCA1, BRCA2 or PALB2 mutations exclude participation.
The idea: alternate a month of NALIRIFOX with a month of gemcitabine plus nab-paclitaxel. Gemcitabine disrupts DNA production; nab-paclitaxel blocks cell division. NALIRIFOX is given every two weeks; the other combination is given on three days per four-week cycle. Groups are not randomized. Researchers assess six-month cancer control and safety.
This phase 2 study plans 41 patients. Northwell sponsors seven recruiting New York sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.